PDS Biotechnology Corporation Common Stock (PDSB) Stock Price

PDSBStock
$1.13+19.50%52W
Market Cap$81.90M
P/E—
PEG Ratio—
Div yield—
Beta1.26

PDSB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-3.30%
Price vs S&P 500 (4W)35.55%
VGM Score71.01

PDSB Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.13-$0.18-42.10%(-$0.05)
Q1 2026-$0.14-$0.13+7.14%(+$0.01)
Q4 2025-$0.20-$0.14+30.00%(+$0.06)
Q3 2025-$0.20-$0.19+3.39%(+$0.01)
Q2 2025-$0.23-$0.21+10.00%(+$0.02)

PDSB Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.11
4.11
4.11
4.11

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
PDSBPDS Biotechnology Corporation Common Stock
——B————$1.13
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About PDS Biotechnology Corporation Common Stock

PDS Biotechnology is a clinical-stage immunotherapy company developing cancer treatments across multiple indications including head and neck, breast, prostate, cervical, and anal cancers. The company's proprietary Versamune platform harnesses the immune system to specifically target cancer cells. Its pipeline is built on this differentiated technology platform.